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quent untargeted TKI. EGFR testing+gefitinib was a dominant economic strategy 
when compared to commonly used treatment alternatives. Assuming the most con-
servative comparator strategies, EGFR+gefitinib remained cost-effective. Decreasing 
the specificity of EGFR testing (false positive rate) or including a mortality benefit to 
TKI worsened the ICER. ConClusions: Simultaneous reimbursement of the EGFR 
test and gefitinib for first-line treatment of EGFR M+ aNSCLC was a cost-effective 
alternative to no testing and chemotherapy.
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objeCtives: Geographic Atrophy (GA) affects eight million people worldwide, lim-
its visual acuity (VA) resulting in blindness. Our aim was to forecast the long term 
impact of GA on visual loss and blindness, and the expected benefits of early treat-
ment. Methods: The model was developed using Excel Visual Basic Application 
(VBA) with the following inputs: 1) population characteristics (gender, age at GA diag-
nosis, baseline VA, one eye versus two eyes involvement), 2) health states by VA (no 
visual impairment, visual impairment, blindness and death), 3) rate of VA decline. 
Data of natural progression of GA from Age-Related Eye Disease Study (AREDS) was 
used as the main input for this model. The key outputs of the model under no inter-
vention/hypothetical intervention are: 1) time to loss of functional vision (VA> 20/40), 
visual impairment (VA< 20/80), and blindness (VA≤ 20/200), and 2) time to event curves 
for visual disability and blindness. Results: In a simulated cohort of 500 patients 
diagnosed with GA (with a mean age of 70 years and VA= 20/60), the model estimated 
that 60% of them would develop blindness in the affected eye over their lifetime 
without intervention. On average, they experience four years with visual impairment 
and eight years with blindness. The model also showed that GA patients with younger 
age and worse VA at diagnosis, and faster rate of VA decline are at increased risk of 
attaining blindness. A hypothetical intervention with 25% and 50% efficacy avoided 
1 and 3 years of blindness, respectively. Sensitivity analysis showed that treatment 
efficacy when compared to starting age, starting VA, and rate of VA loss, had the 
highest impact in reducing time spent in blindness. ConClusions: The simulation 
model based on natural history of GA progression showed that effective treatment 
started early at diagnosis can reduce the burden of vision loss among GA patients.
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scoRes in MuLtiLeVeL Data
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objeCtives: Propensity score matching (PSM) techniques are frequently used in 
analyses of retrospective or observational data. Several approaches have been devel-
oped to account for the hierarchical structure of data in PSM analyses. The aim of this 
study is to identify and review existing multi-level PSM methodologies. Methods: 
Medline and PubMed databases were used to perform a targeted literature review 
to identify studies that use PSM methodologies in multi-level data. The following 
search terms were used: ‘Propensity score’, ‘Multi-level data’, ‘Hierarchical model’ 
and ‘Propensity score matching’. Methodologies that specifically considered the 
challenges of performing PSM with hierarchical data were included in the final 
review. Results: Six strategies were identified in the literature to perform PSM in 
multi-level data. These included 1) Complete pooling (CP); 2) Partial pooling (PP); 3) 
No pooling (NP); 4) Simple single-level modeling (SSLM); 5) “Two stage” modeling 
(TSM); and 6) “Dummy” modeling (DM). CP ignores potential clustering in the data 
and is the most commonly used approach. SSLM differs from CP in that it matches 
patients only within a given cluster. In contrast, the NP method generates separate 
propensity scores (PS) for each cluster and matches prior to pooling. The PP method 
uses random intercept models to generate PS and patients are matched across all 
clusters. The TSM approach first estimates random errors separately and applies 
them in a subsequent PS model that account for clustering, after which patients are 
matched as in the PP method. The DM method simply includes the cluster identifier 
as a fixed effect in the PS model. ConClusions: Performance of each approach is 
dependent on the number of clusters and the sample size in each cluster. A thorough 
investigation of data should be undertaken before selecting an approach to use PSM 
in studies with multi-level data.
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objeCtives: The degree to which predefined risk factor (RF) changes alter life time 
benefits and costs in projections with the IMS-CORE-Diabetes-Model (CDM) has 
been previously reported. The objective of this study was to contrast the relative 
risk reduction of cardiovascular events by individual RF changes using alternative 
risk equations (RE), specifically: UKPDS-68 (UK68-RE), UKPDS-82 (UK82-RE) and the 
Swedish-National-Diabetes-Registry (SNDR-RE). Methods: The CDM was applied 
to estimate annual probabilities for 1st myocardial infarction (MI), 1st stroke, 
ischemic heart disease (IHD) and heart failure (HF) for an intermediate risk type 
2 diabetes individual (age 55 years, HbA1c 8%, SBP 140 mm-Hg, BMI 30 Kg/m2, TC 
250 mg/dl, HDL 50 mg/dl and LDL 170 mg/dl). The relative risk (RR) in association 
with unit RF changes was determined for HbA1c (-1%), body-mass-index (BMI) (-1 
Kg/m2), systolic-blood-pressure (SBP) (-10 mmHg), total-cholesterol (TC) (-10 mg/
dl), (high-density-lipoprotein (HDL) (+5 mg/dl) and low-density-lipoprotein (LDL) 
(-10 mg/dl). Results: The RR of CV endpoints associated with risk factor changes 
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caLibRating an integRateD PhaRMacoeconoMic-PhaRMacoMetRic 
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objeCtives: The objective was to calibrate a pharmacometric-pharmacoeconomic 
microsimulation model of COPD to ensure that variation resulting from model esti-
mates was consistent with the underlying trial data, thereby providing more accurate 
estimates of the probability of the clinical and economic “success” of drug develop-
ment options based on this model. Methods: A Markov microsimulation model was 
developed to estimate monthly changes in key COPD severity metrics (FEV1 and exac-
erbations) in order to compare a hypothetical FEV1-increasing drug to placebo. The 
pharmacometric model, based on a model-based meta-analysis of COPD trials, was 
used to predict the exacerbation rate (ER) in a group of actual trial patients, given their 
known baseline FEV1.The hypothetical drug increased FEV1 and thereby decreased 
the ER in the treatment group. Costs and utilities were derived from the literature and 
applied to monthly model outcomes. The variance in exacerbations generated by this 
model was calibrated to the variance in the trials underlying the pharmacometric 
model. Model results were compared to those generated by a Markov model without 
such calibration. A common random numbers assumption for non-COPD mortality 
was tested for its effect on variation in health economic outcomes. Results: In the 
reference case, relative to the uncalibrated model, the calibrated model resulted in 
similar outcome means but 15-17 times larger standard deviations (SDs) for exacer-
bations, 6-7 times larger SDs for 1-year costs, and three times larger SDs for QALYs. 
This led to more elliptical ICER scatterplots and flatter cost-effectiveness acceptability 
curves in the calibrated model. Use of common random numbers did not make a sig-
nificant difference in these results. ConClusions: Integration of pharmacometric 
and pharmacoeconomic models provides a basis for outcomes variance calibration 
with actual data. Without calibration, variation induced within a typical Markov 
model may substantially misrepresent true clinical variation and lead to inaccurate 
probabilities of success versus clinical and economic thresholds.
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objeCtives: Numerous HPV models have been developed to evaluate the cost-
effectiveness of HPV vaccination. However, uncertainty remains in some key model 
parameters such as the risk of transmission and partner formation and dissolution 
rates. We attempted to identify those parameters that influenced most calibration 
fits for an HPV type 6/11 agent-based model. Methods: We developed an agent-
based HPV model of HPV 6/11 infections and disease (warts) to explore the effect 
of partnership formation and natural history parameters on how well the model 
output fit observed data on HPV 6/11 infections and disease. Our heuristic model 
describes the population in terms of the three groups by individuals’ sexual activity 
level. The activity level is positively correlated with the risk of infection transmission 
or acquisition. Persons belonging to the low and medium risk groups tend to have 
long lasting relationships with low probability of forming concurrent partnerships, 
whereas those in the highest risk (most active) group tend to engage in short and 
often concurrent partnerships. Results: We found that the most sexually active 
group of people is responsible for forming a power-law tail in the partnership statis-
tics reported in surveys and has the biggest impact on the infection spread, and that 
durations of short-term partnerships, along with risk group and age mixing patterns, 
have the biggest impact on the model fit. In combination, these factors also determine 
the characteristic shapes of the warts age-specific incidence curves with the peak 
occurring in the female population approximately five years earlier than in the male 
population. ConClusions: The transmission dynamics of HPV 6/11 infection and 
disease depend greatly on the short-living partnership networks. Accounting for the 
formation of such partnerships is critical to achieving acceptable model fits. Further 
research is necessary to explore how accounting for partnership formation affects 
cost-effectiveness analyses of HPV vaccination strategies.
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objeCtives: A reimbursement process for targeted therapies was introduced in 
2011 requiring joint economic assessment of both the new treatment and associ-
ated diagnostic test. Thus the emphasis of the evaluation was no longer simply 
on the effectiveness of the new treatment in targeted patients but also in patients 
inappropriately treated due to false positive test results. A submission for subsidy 
of EGFR mutation testing to determine eligibility for first-line gefitinib treatment of 
patients with advanced NSCLC was undertaken. Methods: An individual patient 
simulation was used to model current SOC for NSCLC, no test and first-line plati-
num-based doublet chemotherapy versus the proposed intervention, EGFR mutation 
test and gefitinib treatment for EGFR M+ patients and SOC for EGFR M- and EGFR 
unknown patients. The IPASS Study (NCT00322452) confirmed the benefit of TKIs in 
EGFR M+ patients, but also the potential harm to EGFR M- patients in the first-line 
setting. Data were thus available for EGFR M+ and EGFR M- patients treated with 
both gefitinib and SOC. This information was critical to development of a screening 
module and survival curves. Results: EGFR testing regimens to target TKI treat-
ment at various points in the patient’s life from diagnosis through to palliative care 
were compared. The results were most sensitive to choice of comparator such as: 
inclusion of switch maintenance following doublet chemotherapy; proportion of 
patients receiving second-line therapies including targeted TKI; and use of subse-
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dictor variables included demographics, treatment type and length, drug usage, 
healthcare setting and experience, status of treatment, aftercare treatment, and 
nursing specialty. Missing data was not considered in the study. After checking for 
all the assumptions, univariate analysis using chi-square test was performed on the 
entire data as well as the subset. All features with significant relationships in the 
univariate analysis were entered in the forward, backward and stepwise multiple 
logistic models to predict the completion of contract by the nurses. All tests were 
conducted at 5% level of significance. Results: All independent variables had a 
significant relationship with the status of CMP. The model using the entire data did 
not converge. The forward logistic model of the subset data showed that drug usage, 
treatment type, status of treatment in contract, annual income and healthcare 
setting had a higher association with the completion of CMP (p-value= 0.1188). The 
backward logistic model showed that aftercare treatment, type of treatment and 
nursing specialty had a significant association with CMP status (p-value = 0.064). The 
stepwise model converged with aftercare treatment having a significant association 
with the CMP status. ConClusions: In this study, the forward logistic model was 
preferred over the backward or the stepwise model to reduce the bias resulting from 
selection of variables and eliminate the resulting quasi-complete separation of data. 
Therefore, this CMP data for nurses was best fit using the forward logistic model.
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objeCtives: To model total health care costs on end-stage renal disease adult 
patients with and without an usual source of care provider and to evaluate 
whether these costs differ between dialysis and transplant patients. Methods: 
Retrospective cross-sectional data from 197 unique adult patients was collected 
for years 2002 to 2011 using the Medical Expenditure Panel Survey conducted on 
American households. Total cost for renal disease patients was modeled using 
the Bayesian mean regression posterior estimates and was followed by comput-
ing predictive values for a new set of observations. Total cost comprised of total 
costs for office based expenditures, prescription drugs, home health care, inpatient 
care, outpatient care, emergency room visits and costs associated with equipment 
and medical supplies. Results: Among the 197 end-stage renal disease patients, 
43% underwent dialysis and 22% underwent transplantation. Overall for the end-
stage renal disease adults, the mean annual costs of care for a patient with an 
usual source of care provider vs. without an usual source of provider was $28,807 
vs. $20,851. In comparison, the mean annual cost of care for a transplant patient 
without a usual source of care was $19,464 and for a dialysis patient was $92,326. 
Transplant patients with a source of care provider can potentially save 23% in annual 
total cost in comparison to patients without any source of care; dialysis patients can 
save 56% of total cost annually. ConClusions: Transplant and dialysis patients 
having an usual source of care provider incurred less health expenditures. In renal 
disease patients, having an usual source of provider has possibly large implications 
for health care cost savings.
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the use of bootstRaP MoDeL aVeRaging When estiMating suRViVaL 
cuRVes
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objeCtives: To explore the use of bootstrap model averaging (BOOT) for estimating 
survival curves when conducting parametric survival analysis. Methods: A set of 
four clinical trials in advanced soft tissue sarcoma were identified from a published 
systematic review. Individual patient data for overall survival were estimated from 
digitised Kaplan-Meier curves using a published algorithm. A range of parametric 
survival models (exponential, Weibull, Gompertz, lognormal, log-logistic, Gamma 
and Generalised Gamma) were fitted for each study. One thousand bootstrap sam-
ples of the IPD for each study were taken. The model which minimised the Bayesian 
Information Criterion (BIC) was selected for each sample. The proportions of bootstrap 
samples within which each model was selected were used as the weights for the 
BOOT estimate. These were applied to the mean survival estimates obtained from 
each candidate model applied to the original data set to obtain the weighted average 
BOOT estimate of mean survival for each treatment. Results: Estimates of mean 
survival varied markedly according to the choice of functional form for the parametric 
survival model. There was also considerable uncertainty in the selection of an optimal 
functional form based on the BIC (the bootstrap estimation for the probability that the 
optimal model had been selected varied between 16% and 71% across studies). Using 
the results from the BOOT analysis rather than selecting a single functional form 
reduced the estimated variance in mean survival in all studies. ConClusions: BOOT 
can reduce the variance in mean survival estimates and avoids the need for select-
ing a single functional form for a parametric survival model. Given the considerable 
uncertainty in selecting a functional form and the influence of this process on mean 
survival estimates, BOOT could act as a useful method for addressing uncertainty in 
functional form selection and hence in cost-effectiveness analyses.
ReseaRch on MethoDs – Patient-Reported outcomes studies
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for HbA1c, SBP, BMI, TC, HDL and LDL was predicted as follows. MI: 0.89, 0.90, 1.00, 
0.98, 1.36, 1.00 (UK-68-RE), 0.93, 0.95, 1.00, 1.00, 1.00, 0.93 (UK82-RE) and 0.92, 0.92, 
1.00, 0.99, 1.29, 0.98 (SNDR-RE). Stroke: 0.88, 0.76, 1.00, 0.99, 1.18, 1.00 (UK68-RE), 0.91, 
0.84, 1.00, 1.00, 1.00, 0.97 (UK82-RE) and 0.85, 0.94, 1.00, 0.99, 1.18, 1.00 (SNDR). IHD: 
0.85, 0.89, 0.94, 1.00, 1.00, 1.00 (UK68-RE), 1.00, 0.94, 1.00, 1.00, 1.21, 0.96 (UK82-RE) 
and 0.94, 1.00, 0.98, 0.99, 1.29, 1.00 (SNDR-RE). HF: 0.88, 0.91, 1.00, 0.98, 1.48, 1.00 
(UK68-RE), 1.00, 1.00, 0.93, 1.00, 1.00, 0.98 (UK82-RE) and 0.83, 0.83, 0.94, 0.99, 1.19, 
1.00 (SNDR-RE). ConClusions: The degree to which RF modification influences 
CV risk can vary considerably, dependent on RE selected. The choice of equation 
within a model may influence the predicted health economic benefit associated 
with CV risk factor modification.
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objeCtives: The cost-effectiveness type 2 diabetes mellitus (T2DM) therapies are 
often driven by changes in HbA1c, weight and hypoglycaemia rates. There are a 
number of risk equations available for modeling diabetes complications. The objec-
tive of this study was to attribute the predicted gain in quality adjusted life years 
(QALYs) to HbA1c, weight and hypoglycaemia change for each of the UKPDS-68 
risk equations (UK-68-RE); the UKPDS-82 risk equations (UK-28-RE), the Swedish-
National-Diabetes-Registry RE (S-NDR) and ADVANCE RE (A-RE). Methods: 
Published data on T2DM switching to insulin degludec from either insulin glargine 
or detemir were used. Mean (± SD) baseline profiles were age 62.8 years (± 14.7); 
diabetes duration 16.2 years (± 5.0); HbA1c 9.4% (±1.1); weight 102.8 kg (±23.0) and 1.0 
hypoglycaemia events per week (±1.4). Mean 1-year change in clinical variables was 
HbA1c -0.7% (±0.3); weight -1.3kg (±1.1) and hypoglycaemia events/week -1.0 (±1.3). 
The CDM, with lifetime perspective, was used calculate the incremental QALYs pre-
dicted associated with either the UK-68-RE; UK-82-RE, S-NDR RE and A-RE. Results 
were discounted at 3%. Results: With UK-68-RE total QALYs for insulin degludec 
were 7.747 (QALY gain of 3.306 vs. basal insulin); 2.84%, 97.73% and -0.57% were 
attributable to HbA1c, hypoglycemia and weight change respectively. For UK-82-RE, 
total QALYs were 7.718 (QALY gains 3.306), 2.90%, 97.43% and -0.33% attributable to 
HbA1c, hypoglycemia and weight change respectively. For S-NDR-RE total QALYs 
were 5.937 (QALY gains 2.68), 3.47%, 97.24% and -0.71% attributable to HbA1c, hypo-
glycaemia and weight change. Finally, for ADVANCE-RE total QALYs were 7.035 (QALY 
gains 2.987), 2.31%, 98.32% and -0.63% attributable to HbA1c, hypoglycaemia and 
weight change respectively. ConClusions: HbA1c reduction is not necessarily 
the key driver of health benefit within diabetes models. Validating costs and health 
utilities associated with changes in weight and hypoglycaemia frequency are as 
important as justifying choice of risk equations used.
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objeCtives: In health technology assessment (HTA), decision-makers face increased 
pressures to make earlier decisions. However, in early stages of drug development, 
data on effectiveness of new health technologies measured by the final outcome 
is often limited, especially when measuring the effectiveness of new interventions 
requires long follow-up time. Therefore, shorter-term surrogate endpoints play an 
important role in HTA. Candidate surrogate endpoints do not always proove to be 
perfect. However, when more than one of such endpoints exists, they may jointly fully 
mediate the treatment effect on the final outcome. This study presents methodology 
for evaluation of multiple surrogate endpoints as predictors of the treatment effect on 
the final outcome. Methods: Meta-analytical methods for the evaluation of multiple 
surrogate endpoints are developed. The modelling techniques, developed in Bayesian 
framework, take into account measurement errors of the treatment effects on all out-
comes and the correlations between them. Methods developed are applied to a case 
study in multiple sclerosis (MS) where the relapse rate (RR) and the number of active 
MRI lesions (MRI) are the candidate surrogate endpoints and the final outcome is the 
disability progression (DP). Surrogate endpoints are evaluated by assessing their pre-
dictive value in the cross-validation procedure. Results: Applying bivariate model 
showed a good association between effects on RR and DP. Extending to trivariate case 
to include the effect on MRI increased the precision of the association and reduced the 
heterogeneity. The cross validation gave better predictions, by reducing the intervals 
on average by 14%, when including multiple surrogate endpoints. ConClusions: 
The methods used for combining evidence on multiple surrogate outcomes can lead 
to more precise predictions of the effect on final outcome. Inclusion of multiple sur-
rogate endpoints may lead to a more substantial gain in precision in other disease 
areas, hence leading to faster HTA decisions.
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objeCtives: The main goal of this research is to determine the factors which best 
predict the completion of a nurse substance abuse monitoring program. Methods: 
A retrospective cross sectional analysis was conducted in a state database (Florida) 
of 65,000 nurses enrolled in CMP. The entire dataset and the subset of 10,000 were 
used for analysis. The outcome variable was the status of CMP program. The pre-
